PM
Philip Morris International Inc.Evidence as of 2026-09-11The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on PM
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · Philip Morris International Inc.
Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company…
Management team
- Mr. Stefano Volpetti · President of Smoke-Free Inhalable Products & Chief Consumer OfficerFind on LinkedIn
- Ms. Stacey Kennedy · President of Americas Region & CEO of US BusinessFind on LinkedIn
- Mr. Frederic de Wilde · President of South & Southeast Asia, Commonwealth of Ind. States and Middle East & Africa RegionFind on LinkedIn
- Mr. Emmanuel Babeau · Chief Financial OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.2 on a −2 to +2 scale (was −0.1 before the debate changed the read).
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.2 of a possible +2; was -0.1 before debate) · confidence high. Financial results show sequential improvement: revenue rose from $ 10,146,000,000 in fiscal Q1 2026 (fiscal quarter ended 2026-04-17) to $ 11,192,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-07-17), gross profit increased from $ 6,905,000,000 to $ 7,659,000,000 and gross margin edged from about 68.0% to about 68.4%. Operating income moved from $ 3,893,000,000 to $ 4,530,000,000 (operating margin ~ 38.4% to ~ 40.5%), and net income rose from $ 2,438,000,000 to $ 2,817,000,000 with diluted EPS increasing from $ 1.56 to $ 1.80.
Market and capital structure signals coexist: price is slightly above the 50‑ and 200‑day SMAs with a golden cross flagged, momentum readings are positive across horizons, volatility is elevated (30d annualized ~ 23.8%, 90d ~ 28.9%), trailing P/E is 25.17 on EPS of $ 7.54, trailing EV/EBITDA is 16.65, trailing FCF is negative $ 2,916,000,000, cash rose to $ 5,999,000,000 while reported total liabilities fell to $ 74,928,000,000, and stockholders’ equity remained negative $ 8,583,000,000.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue was $10,146,000,000 for fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $11,192,000,000 for fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), implying a quarter-to-quarter increase of $1,046,000,000 between those fiscal quarters.
XBRL companyfacts · 0001628280-26-027019Gross profit was $6,905,000,000 for fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $7,659,000,000 for fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), representing gross margins of about 68.0% in fiscal Q1 2026 and about 68.4% in fiscal Q2 2026 (gross profit ÷ revenue for each quarter).
XBRL companyfacts · 0001628280-26-027019Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The 10-K filed 6 February 2026 (the 10-K filed 6 February 2026) added a risk that regulators may prohibit or significantly restrict the commercialization of smoke-free products or the communication of scientifically substantiated information and claims about them.
10-K filed 2026-02-06The risk-factor diff shows the company added language that its strategic priority to introduce, commercialize and grow SFPs could be 'materially adversely impacted' if those efforts are unsuccessful, if competitors are more successful, or if certain SFP categories are inequitably regulated.
10-K filed 2026-02-06Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Momentum readings are positive across horizons: momentum_3m is +4.6%, momentum_6m is +14.8%, and momentum_12_1 is +12.5%; the 6-month momentum ranks in the 70th percentile of the 554-stock research universe while the 12-1 momentum ranks in the 48th percentile of 554.
Moneyta signal set · 2026-09-10weakened in debatePrice is trading slightly above short- and long-term moving averages: price_vs_sma50 is +0.8% and price_vs_sma200 is +9.0%, and a golden_cross is flagged (cross_age_days = 147).
Moneyta signal set · 2026-09-10Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
The aggregated 13F-reported institutional holdings value was "$209.38B" as of 2026-03-31 (13F filings carry a 45-day reporting lag).
13F holdings · 2841 filers · as of 2026-03-31Capital World Investors was the largest reported 13F holder with "$22.06B" as of 2026-03-31.
13F holdings · 2841 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Headlines report Philip Morris's CEO describing strong demand and being "optimistic" about Zyn's potential, and mention the company discussing larger can sizes (15–20 pouches) as a revenue idea.
News · finance.yahoo.com · 2026-09-10Coverage notes that Philip Morris revised its full-year outlook to reflect a favorable foreign-exchange impact of about $0.24 per share at current spot rates and attributed smoke-free product momentum (IQOS, ZYN) to growth commentary.
News · finance.yahoo.com · 2026-09-09Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Morparia Kalpana (Director) acquired 1,119 shares valued at "$190k" on 2026-05-06 (action code A); the filing shows no trading-plan flag.
Form 4 · Morparia Kalpana (Director) · $190k code A · 2026-05-06Calantzopoulos Andre (Director) acquired 1,119 shares valued at "$190k" on 2026-05-06 (action code A); the filing shows no trading-plan flag.
Form 4 · Calantzopoulos Andre (Director) · $190k code A · 2026-05-06Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Price per share used in this analysis was $189.77 as of the price date 2026-09-10.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve‑month GAAP earnings per share (EPS) were $7.54 and the trailing P/E (price-to-earnings) multiple is 25.17.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Recent quarterly results show sequential revenue, gross profit, operating income and net income improvements with rising EPS and expanding operating margin, while cash balances increased and total liabilities declined — together these items signal improving near‑term operating performance and stronger cash positioning in the reported periods. Market signals (positive momentum across horizons, price above moving averages, a golden cross, a 3.1% dividend yield and low correlation to the S&P 500) and multiple reported insider acquisitions and increased institutional reported holdings provide corroborating market and shareholder-interest evidence. These operational and market items jointly counterbalance isolated headline risks and valuation noise by showing concurrent earnings strength, margin expansion and institutional engagement across the supplied evidence set.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.32
45 surviving claims rest on 22 distinct sources; the heaviest analyst carries 20% of them, and 99% of what the desk raised survived the debate.
The evidence set is moderately concentrated: many surviving claims rely on a modest number of distinct sources and a single analyst contributes a fifth of the claims, which raises sensitivity to that analyst's interpretations. Because 99% of raised points survived the desk debate, the claims show internal consistency, but source concentration and analyst dependence reduce how independently confirmable the whole read is.
Peer context · computed, not argued
12-1 momentum ranks 1st of 2 in Tobacco (as of 2026-09-10).
90-day volatility ranks 2nd of 2 in Tobacco (as of 2026-09-10).
dividend yield ranks 2nd of 2 in Tobacco (as of 2026-09-10).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
11 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.8 to the score
6 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−1.7 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.3 to the score
2 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.6 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
9 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot+1.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on PM Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.